Cheryl Spence
Hoffmann-La Roche
11 Papers
104 Citations
Cheryl Spence is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Affinity chromatography & Glucokinase. The author has an hindex of 8, co-authored 11 publications. Previous affiliations of Cheryl Spence include University of Pennsylvania.
Chat about Author
Papers
Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.
Pascal Bailon,Palleroni Alicia Vallejo,Carol Ann Schaffer,Cheryl Spence,Wen-Jian Fung,Jill E. Porter,George Ehrlich,Wen Pan,Zhi-Xin Xu,Marlene W. Modi,and Adrienne Farid,Wolfgang Berthold,Mary Graves +12 more
TL;DR: Results of Phase II/III hepatitis C clinical trials in humans confirmed the superior efficacy of pegylated interferon alpha-2a compared to unmodified interferons alpha- 2a.
724
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
Ramakanth Sarabu,Fred Thomas Bizzarro,Wendy Lea Corbett,Mark T. Dvorozniak,Wanping Geng,Joseph F. Grippo,Nancy-Ellen Haynes,Stanley D. Hutchings,Lisa M. Garofalo,Kevin Richard Guertin,Darryl W. Hilliard,Marek M. Kabat,Robert Francis Kester,Wang Ka,Zhenmin Liang,Paige Erin Mahaney,Linda Marcus,Franz M. Matschinsky,David J Moore,Jagdish Kumar Racha,Roumen Nikolaev Radinov,Yi Ren,Lida Qi,Michael Pignatello,Cheryl Spence,Thomas G. Steele,John Tengi,Joseph Grimsby +27 more
TL;DR: Piragliatin was found to lower pre- and postprandial glucose levels, improve the insulin secretory profile, increase β-cell sensitivity to glucose, and decrease hepatic glucose output in patients with T2D.
90
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
Nancy-Ellen Haynes,Wendy Lea Corbett,Fred Thomas Bizzarro,Kevin Richard Guertin,Darryl W. Hilliard,George W. Holland,Robert Francis Kester,Paige Erin Mahaney,Lida Qi,Cheryl Spence,John Tengi,Mark T. Dvorozniak,Aruna Railkar,Franz M. Matschinsky,Joseph F. Grippo,Joseph Grimsby,Ramakanth Sarabu +16 more
TL;DR: Identification of the hit molecule 1 and its SAR development, which led to the discovery of potent allosteric GK activators 9a and 21a, is described and compound 21a was used to validate the clinical relevance of targeting GK to treat type 2 diabetes.
42
Fluidized‐bed receptor‐affinity chromatography
TL;DR: Overall, fluidized-bed receptor-affinity chromatography is found to be a productive affinity method suitable for the purification of recombinant human interleukin-2 and related molecules.
20